|
Originally published In Press as doi:10.1074/jbc.M204568200 on June 4, 2002
J. Biol. Chem., Vol. 277, Issue 32, 28795-28802, August 9, 2002
Ameliorated Hepatic Insulin Resistance Is Associated with
Normalization of Microsomal Triglyceride Transfer Protein Expression
and Reduction in Very Low Density Lipoprotein Assembly and Secretion in
the Fructose-fed Hamster*
André
Carpentier §,
Changiz
Taghibiglou¶,
Nathalie
Leung ,
Linda
Szeto ,
Stephen C.
Van Iderstine¶,
Kristine D.
Uffelman ,
Robin
Buckingham ,
Khosrow
Adeli¶, and
Gary F.
Lewis **
From the Department of Medicine, Division of
Endocrinology and Metabolism, University Health Network, and
¶ Department of Laboratory Medicine and Pathobiology, Hospital for
Sick Children, University of Toronto, Toronto, Ontario M5G 2C4,
Canada, and GlaxoSmithKline, Clinical Development & Medical
Affairs, New Frontiers Science Park (South),
Harlow, Essex CM19 5AW, United Kingdom
To determine whether reduction of
insulin resistance could ameliorate fructose-induced very low density
lipoprotein (VLDL) oversecretion and to explore the mechanism of this
effect, fructose-fed hamsters received placebo or rosiglitazone for 3 weeks. Rosiglitazone treatment led to normalization of the blunted
insulin-mediated suppression of the glucose production rate and to a
~2-fold increase in whole body insulin-mediated glucose disappearance
rate (p < 0.001). Rosiglitazone ameliorated the
defect in hepatocyte insulin-stimulated tyrosine phosphorylation of the
insulin receptor, IRS-1, and IRS-2 and the reduced protein mass of
IRS-1 and IRS-2 induced by fructose feeding. Protein-tyrosine
phosphatase 1B levels were increased with fructose feeding and were
markedly reduced by rosiglitazone. Rosiglitazone treatment led to a
~50% reduction of VLDL secretion rates (p < 0.05)
in vivo and ex vivo. VLDL clearance assessed directly in vivo was not significantly different in the FR
(fructose-fed + rosiglitazone-treated) versus F
(fructose-fed + placebo-treated) hamsters, although there was a trend
toward a lower clearance with rosiglitazone. Enhanced stability of
nascent apolipoprotein B (apoB) in fructose-fed hepatocytes was
evident, and rosiglitazone treatment resulted in a significant
reduction in apoB stability. The increase in intracellular mass of
microsomal triglyceride transfer protein seen with fructose feeding was
reduced by treatment with rosiglitazone. In conclusion, improvement of
hepatic insulin signaling with rosiglitazone, a peroxisome
proliferator-activated receptor agonist, is associated with reduced
hepatic VLDL assembly and secretion due to reduced intracellular apoB stability.
*
These studies were supported in part by operating grants
from the Canadian Institutes of Health Research, Heart and Stroke Foundation of Ontario and GlaxoSmithKline.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a Heart and Stroke Foundation of Canada/Medical
Research Council cardiovascular research fellowship and currently a New
Investigator of the Canadian Institutes of Health Research.
**
Holds a Canada Research Chair in Diabetes and a Scientist of the
Heart and Stroke Foundation of Canada. To whom correspondence should be
addressed: Division of Endocrinology and Metabolism, Toronto General
Hospital, 200 Elizabeth St., Room EN11-229, Toronto, Ontario M5G 2C4,
Canada. Tel.: 416-340-4270; Fax: 416-340-3314; E-mail:
gary.lewis@uhn.on.ca.
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
W. Huang, A. Metlakunta, N. Dedousis, H. K. Ortmeyer, M. Stefanovic-Racic, and R. M. O'Doherty
Leptin Augments the Acute Suppressive Effects of Insulin on Hepatic Very Low-Density Lipoprotein Production in Rats
Endocrinology,
May 1, 2009;
150(5):
2169 - 2174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Laplante, W. T. Festuccia, G. Soucy, P.-G. Blanchard, A. Renaud, J. P. Berger, G. Olivecrona, and Y. Deshaies
Tissue-specific postprandial clearance is the major determinant of PPAR{gamma}-induced triglyceride lowering in the rat
Am J Physiol Regulatory Integrative Comp Physiol,
January 1, 2009;
296(1):
R57 - R66.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Chen, E. P. Newberry, J. Y. Norris, Y. Xie, J. Luo, S. M. Kennedy, and N. O. Davidson
ApoB100 is required for increased VLDL-triglyceride secretion by microsomal triglyceride transfer protein in ob/ob mice
J. Lipid Res.,
September 1, 2008;
49(9):
2013 - 2022.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Duez, B. Lamarche, K. D. Uffelman, R. Valero, L. Szeto, S. Lemieux, J. S. Cohn, and G. F. Lewis
Dissociation between the Insulin-Sensitizing Effect of Rosiglitazone and Its Effect on Hepatic and Intestinal Lipoprotein Production
J. Clin. Endocrinol. Metab.,
May 1, 2008;
93(5):
1722 - 1729.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Qin, R. A. Anderson, and K. Adeli
Tumor necrosis factor-{alpha} directly stimulates the overproduction of hepatic apolipoprotein B100-containing VLDL via impairment of hepatic insulin signaling
Am J Physiol Gastrointest Liver Physiol,
May 1, 2008;
294(5):
G1120 - G1129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Laplante, W. T. Festuccia, G. Soucy, Y. Gelinas, J. Lalonde, and Y. Deshaies
Involvement of adipose tissues in the early hypolipidemic action of PPAR{gamma} agonism in the rat
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 2007;
292(4):
R1408 - R1417.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Qu, D. Su, J. Altomonte, A. Kamagate, J. He, G. Perdomo, T. Tse, Y. Jiang, and H. H. Dong
PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1
Am J Physiol Endocrinol Metab,
February 1, 2007;
292(2):
E421 - E434.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Duez, B. Lamarche, K. D. Uffelman, R. Valero, J. S. Cohn, and G. F. Lewis
Hyperinsulinemia Is Associated With Increased Production Rate of Intestinal Apolipoprotein B-48-Containing Lipoproteins in Humans
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2006;
26(6):
1357 - 1363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Burgermeister, A. Schnoebelen, A. Flament, J. Benz, M. Stihle, B. Gsell, A. Rufer, A. Ruf, B. Kuhn, H. P. Marki, et al.
A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor-{gamma} (PPAR{gamma}) Recruits PPAR{gamma}-Coactivator-1{alpha}, Prevents Triglyceride Accumulation, and Potentiates Insulin Signaling in Vitro
Mol. Endocrinol.,
April 1, 2006;
20(4):
809 - 830.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Adiels, J. Boren, M. J. Caslake, P. Stewart, A. Soro, J. Westerbacka, B. Wennberg, S.-O. Olofsson, C. Packard, and M.-R. Taskinen
Overproduction of VLDL1 Driven by Hyperglycemia Is a Dominant Feature of Diabetic Dyslipidemia
Arterioscler. Thromb. Vasc. Biol.,
August 1, 2005;
25(8):
1697 - 1703.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. M. Allister, N. M. Borradaile, J. Y. Edwards, and M. W. Huff
Inhibition of Microsomal Triglyceride Transfer Protein Expression and Apolipoprotein B100 Secretion by the Citrus Flavonoid Naringenin and by Insulin Involves Activation of the Mitogen-Activated Protein Kinase Pathway in Hepatocytes
Diabetes,
June 1, 2005;
54(6):
1676 - 1683.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-P. F. Morand, J. Macri, and K. Adeli
Proteomic Profiling of Hepatic Endoplasmic Reticulum-associated Proteins in an Animal Model of Insulin Resistance and Metabolic Dyslipidemia
J. Biol. Chem.,
May 6, 2005;
280(18):
17626 - 17633.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Ameen, U. Edvardsson, A. Ljungberg, L. Asp, P. Akerblad, A. Tuneld, S.-O. Olofsson, D. Linden, and J. Oscarsson
Activation of Peroxisome Proliferator-activated Receptor {alpha} Increases the Expression and Activity of Microsomal Triglyceride Transfer Protein in the Liver
J. Biol. Chem.,
January 14, 2005;
280(2):
1224 - 1229.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. F. Lewis, K. Uffelman, M. Naples, L. Szeto, M. Haidari, and K. Adeli
Intestinal Lipoprotein Overproduction, a Newly Recognized Component of Insulin Resistance, Is Ameliorated by the Insulin Sensitizer Rosiglitazone: Studies in the Fructose-Fed Syrian Golden Hamster
Endocrinology,
January 1, 2005;
146(1):
247 - 255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Qiu, R. K. Avramoglu, N. Dube, T. M. Chong, M. Naples, C. Au, K. G. Sidiropoulos, G. F. Lewis, J. S. Cohn, M. L. Tremblay, et al.
Hepatic PTP-1B Expression Regulates the Assembly and Secretion of Apolipoprotein B-Containing Lipoproteins: Evidence From Protein Tyrosine Phosphatase-1B Overexpression, Knockout, and RNAi Studies
Diabetes,
December 1, 2004;
53(12):
3057 - 3066.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. F. Lewis, S. Murdoch, K. Uffelman, M. Naples, L. Szeto, A. Albers, K. Adeli, and J. D. Brunzell
Hepatic Lipase mRNA, Protein, and Plasma Enzyme Activity Is Increased in the Insulin-Resistant, Fructose-Fed Syrian Golden Hamster and Is Partially Normalized by the Insulin Sensitizer Rosiglitazone
Diabetes,
November 1, 2004;
53(11):
2893 - 2900.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. F. Lewis, M. Naples, K. Uffelman, N. Leung, L. Szeto, and K. Adeli
Intestinal Lipoprotein Production Is Stimulated by an Acute Elevation of Plasma Free Fatty Acids in the Fasting State: Studies in Insulin-Resistant and Insulin-Sensitized Syrian Golden Hamsters
Endocrinology,
November 1, 2004;
145(11):
5006 - 5012.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Berthiaume, H. Sell, J. Lalonde, Y. Gelinas, A. Tchernof, D. Richard, and Y. Deshaies
Actions of PPAR{gamma} agonism on adipose tissue remodeling, insulin sensitivity, and lipemia in absence of glucocorticoids
Am J Physiol Regulatory Integrative Comp Physiol,
November 1, 2004;
287(5):
R1116 - R1123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Alam, M. Stolinski, C. Pentecost, M. A. Boroujerdi, R. H. Jones, P. H. Sonksen, and A. M. Umpleby
The Effect of a Six-Month Exercise Program on Very Low-Density Lipoprotein Apolipoprotein B Secretion in Type 2 Diabetes
J. Clin. Endocrinol. Metab.,
February 1, 2004;
89(2):
688 - 694.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Morel, S. Demignot, D. Chateau, J. Chambaz, M. Rousset, and F. Delers
Lipid-dependent Bidirectional Traffic of Apolipoprotein B in Polarized Enterocytes
Mol. Biol. Cell,
January 1, 2004;
15(1):
132 - 141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W.-S. Au, H.-f. Kung, and M. C. Lin
Regulation of Microsomal Triglyceride Transfer Protein Gene by Insulin in HepG2 Cells: Roles of MAPKerk and MAPKp38
Diabetes,
May 1, 2003;
52(5):
1073 - 1080.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|